To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Broad-Based Black Economic Empowerment Act: Annual Compliance Report

Release Date: 11/08/2017 15:00
Code(s): MEI     PDF:  
Wrap Text
Broad-Based Black Economic Empowerment Act: Annual Compliance Report

Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic” or “the Company”)

11 August 2017

BROAD-BASED BLACK ECONOMIC EMPOWERMENT ACT: ANNUAL COMPLIANCE REPORT

In accordance with the JSE Listings Requirements, applicable to the Company having a secondary
listing on the JSE, notice is hereby given that the Company’s annual compliance report in terms of
section 13G(2) of the South African Broad-Based Black Economic Empowerment Act, 53 of 2003, as
amended, (the “B-BBEE Act”) was submitted to the Broad-Based Black Economic Empowerment
Commission. The compliance report is available in the governance section of Mediclinic’s website at
www.mediclinic.com.

The compliance report relates to the assessment of the broad-based black economic empowerment
status of Mediclinic Southern Africa (Pty) Ltd, a wholly-owned subsidiary of the Company, in respect of
the Company’s operations in South Africa.

About the B-BBEE Act

The B-BBEE Act was enacted to establish a legislative framework for the promotion of broad-based
black economic empowerment in South Africa and is intended to encourage transformation by including
black people in the economy. It covers aspects such as ownership, management control, skills
development, enterprise and supplier development and social-economic development. Although
compliance with the B-BBEE Act and the Codes of Good Practice issued in terms thereof is voluntary,
an obligation was introduced by way of an amendment to the B-BBEE Act in 2013, which became
effective in June 2016, to require public companies listed on the JSE Limited to report on their broad-
based black economic empowerment status to the Broad-Based Black Economic Empowerment
Commission (the “BEE Commission”).

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South
Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the
quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-
based private healthcare group.

Mediclinic comprises 75 hospitals and 29 clinics. Mediclinic Southern Africa operates 49 hospitals and
2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in
total; Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1
700 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 23 clinics with more than 700
inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group
plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International
Limited was completed. Mediclinic International Limited was a South African based international private
healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986,
with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai).
The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in
South Africa and the NSX in Namibia.
For further information, please contact:

Mediclinic Southern Africa
Tertia Kruger, Corporate Communications Manager
Tel: +27 (0)21 809 6500
Email: tertia.kruger@mediclinic.co.za

Capita Company Secretarial Services Limited
Victoria Dalby / Caroline Emmet
+44 (0)20 7954 9600

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 11/08/2017 03:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story